Trial Profile
Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 patients refractory to pegylated interferon
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Dec 2008
Price :
$35
*
At a glance
- Drugs Boceprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Schering-Plough
- 08 Dec 2008 New trial record.